Revenue segments as reported by the company.

Premiums

Services

Investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefits

Operating costs

Depreciation and amortization

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Humana

Humana Inc. engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental plans such as Medicare, and State-based contracts. The Group and Specialty segment contains employer group fully-insured commercial medical products and specialty health insurance benefits marketed to individuals and groups, including dental, vision, military services and other supplemental health & voluntary insurance. The Healthcare Services segment offers services such as pharmacy solutions, provider services, clinical care, predictive modeling and informatics to other Humana businesses, as well as external health plan members, and other employers. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Humana exceeds earnings expectations, focuses on value-based care growth

Humana's strong financial performance and growth in value-based care position the company well for future success. Addressing audit error rates, uncertainties around RADV, and managing costs are key challenges. Opportunities in recruiting, revenue growth, and strategic partnerships offer avenues for further growth.

Humana exceeds Q1 expectations, eyes industry growth amidst challenges

Humana's strong Q1 performance and strategic decisions position it well for growth
Challenges like rate disruptions and Medicaid redeterminations require close monitoring
Opportunities in industry growth, member engagement, and benefit enhancements ahead
Commitment to long-term goals and high-quality service evident in company's outlook

Humana meets Q2 expectations, eyes growth in MA platform

Humana's Q2 performance met expectations with a focus on MA platform growth and disciplined investments.
Challenges include higher utilization in Medicare Advantage and broad-based medical cost trends.
Strategic benefits adjustments and competitive positioning present opportunities for growth and margin expansion.
Expectations for 2024 include maintaining market share, offsetting costs, and achieving strong membership growth.

Humana surpasses Q3 earnings expectations, eyes $37 EPS target

Humana's Q3 performance exceeded expectations, with strong membership growth and strategic initiatives driving future profitability.
While facing challenges in benefit ratios and regulatory changes, Humana remains focused on achieving long-term financial targets.
The company's commitment to operational excellence, membership growth, and pricing actions positions it for sustained success.
Strategic partnerships and risk management efforts showcase Humana's resilience and adaptability in a dynamic healthcare landscape.

Humana faces challenges from rising costs but eyes long-term growth

Humana's Q4 2023 earnings call highlighted challenges from increased medical costs and utilization trends impacting financial performance and outlook.
Despite disappointments in short-term results, the company remains confident in the long-term attractiveness of the Medicare Advantage sector.
Strategic efforts to restore margins, address utilization drivers, and engage with providers reflect a proactive approach to managing industry dynamics.
Balancing profitability with membership growth through benefit adjustments and pricing actions is crucial for Humana's sustainable financial performance.

Humana reports solid Q1 performance, eyes margin recovery in 2025

Humana's Q1 2024 earnings call highlighted a strong start to the year, challenges in the industry for 2025, and a focus on margin recovery and growth opportunities. The company remains confident in its outlook, emphasizing pricing discipline and maintaining a strong value proposition in the market.

Humana surpasses Q2 expectations, addresses cost pressures for growth

Humana's Q2 2024 performance exceeded expectations, driven by strong Medicare business and growth in Medicaid and primary care segments.
Challenges such as medical cost pressures were addressed through mitigation measures, while opportunities lie in strategic initiatives and long-term planning.
The company's focus on value, disciplined cost management, and operational efficiency position it well for sustained growth and value creation.

Humana surpasses Q3 expectations, eyes growth through efficiency and investments

Humana's Q3 performance exceeded expectations, with a focus on balancing earnings and investments. The company is strategically positioned to drive growth through membership expansion and operational efficiency. Challenges include managing costs and understanding market dynamics, with opportunities in improving Stars ratings and expanding senior care services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

CVS Health

UnitedHealth Group

Humana, CVS, and UnitedHealth all fell after the CMS approved a 3.7% payment rate increase for Medicare Advantage plans for 2025. "Core" payments are actually expected to decline slightly after accounting for higher utilization trends.

Why Shares of UnitedHealth Group, CVS Health, and Humana Fell Today

Archer Aviation

Albemarle

APA Corporation

Air Products and Chemicals

Bunge Global SA

Charter Communications

Tesla

V.F.

Warner Bros Discovery Inc

In an orderly world, companies would increase revenue and profits steadily to support a continual lifting of earnings estimates and price targets for stocks. But life is never simple.

These stocks' price targets have been cut the most by Wall Street analysts in 2024

Medicare Advantage payment rates for 2025 came in short of investor expectations.

Wall Street's Love Affair With Humana Stock Is Ending in Tears

Cigna

Health insurance stocks are falling on Tuesday after President Joe Biden's Administration announced it won't increase Medicare Advantage rates for 2025. This comes as a surprise to health insurance companies as the government typically increases its rates compared to its initial proposals.

Why Are Health Insurance Stocks HUM, UNH, CI Down Today?

Centene

Elevance Health Inc

The rate adds more pressure on insurers already grappling with high medical costs and uncertainty after the cyberattack on UnitedHealth Group's tech unit.

Health insurer stocks slide as final Medicare Advantage rates disappoint

Higher costs and lower hikes in rates can lead to lower profit growth, which concerns investors.

Health Insurance Stocks Drop: Insights Into the Late Monday Fall

COLUMBUS, Ohio--(BUSINESS WIRE)--Humana Healthy Horizons – Ohio partners with CPESN® USA to expand access to pharmacists.

Humana Healthy Horizons – Ohio partners with CPESN® USA to expand access to pharmacists

Disc Medicine Inc

Syros Pharmaceuticals

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 3 Health Care Stocks You'll Regret Missing This Month - Humana (NYSE:HUM), Disc Medicine (NASDAQ:IRON)

Shares of health insurers providing Medicare Advantage plans were hit hard Tuesday, after the Centers for Medicare and Medicaid Services announced a payment rate that disappointed investors looking for a bigger increase.

Medicare Advantage rate disappointment sinks stocks of UnitedHealth, Humana

Humana Inc (NYSE: HUM) is down nearly 10% this morning after the U.S. regulators decided against increasing payments for Medicare Advantage plans. Humana investors were hoping for a bigger increase The Centers for Medicare and Medicaid Services, on Tuesday, announced an average increase of 3.7% in private Medicare plans revenue for 2025.

What made Humana stock lose 10% on Tuesday?

Shares of U.S. health insurers dropped between 4% and 9% premarket on Tuesday after reimbursement rates to providers of Medicare Advantage health plans were unchanged from the initial proposal, raising worries about a squeeze on margins next year.

US health insurers slide as final Medicare Advantage rate sparks margin hit fears

Humana (HUM) led after-hours declines in healthcare stocks Monday evening, dropping nearly 10% after the Centers for Medicare & Medicaid Services (CMS) announced that federal payments to Medicare Advantage plans will match the initial proposal outlined in January, effectively crimping health insurers' profit margins amid rising medical costs.

Humana Stock Slides as Medicare Advantage Rate Rise Disappoints—Key Level to Watch

Humana (HUM) concluded the recent trading session at $351.45, signifying a +1.36% move from its prior day's close.

Humana (HUM) Increases Despite Market Slip: Here's What You Need to Know

Molina Healthcare

UnitedHealth, Humana and other big health insurers fell Monday night on lower-than-expected Medicare Advantage rates for 2025.

UnitedHealth, Health Insurers Tumble On Medicare Advantage Rates

Amazon

Baxter

Brookfield Renewable Partners

British American Tobacco

Comcast

Global Payments

HDFC Bank Limited

Rexford Industrial Realty

Truist Financial

VictoryShares Free Cash Flow ETF

The market is near record highs and NVDA is up 11 straight weeks. Yet, blue-chip coiled spring bargains are still bountiful. VFLO is the best deep value strategy ETF I've found. A great combo of deep value, quality, and growth. It's beating the S&P, value, and even the Nasdaq since inception. Combining ETFs with individual stocks is a great way to potentially achieve superior returns and yield than ETFs can achieve.

10 Coiled Spring Blue-Chip Bargain Buys

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Is It Worth Investing in Humana (HUM) Based on Wall Street's Bullish Views?

Humana (HUM) closed the most recent trading day at $347.09, moving -0.42% from the previous trading session.

Humana (HUM) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Humana (HUM) collaborates with DUOS to develop a program that aims to provide personalized care and assure the well-being of Louisiana's Veteran community, who have a HUM MA plan and suffer from chronic conditions.

Humana (HUM), DUOS Unveil Program to Improve Veterans' Health

Humana (NYSE: HUM) currently trades around $350 per share, 30% below its peak level of over $500 seen in September 2022, and it seems like it can see higher levels over time. HUM stock was trading at around $470 in June 2022, just before the Fed started increasing rates, and is still 25% below that level.

Should You Pick Humana Stock After A 25% Fall This Year?

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) and DUOS, a technology-enabled service provider announces a new collaborative program to enhance the healthcare experience and improve health outcomes for Louisiana Veteran members with chronic conditions. “When healthcare professionals and systems are responsive to their patients' cultural backgrounds – which includes Veteran status – patients are more likely to receive appropriate care, show up to appointments, follow through with trea.

Humana and DUOS Launch Groundbreaking Initiative Enhancing Care for U.S. Veteran Seniors

Humana's earnings guidance for 2024 and 2025 fell short of analysts' expectations, driven by challenges in its Medicare Advantage business segment. Analysts have drastically cut their income projections for HUM, but still expect the company to grow its earnings at a steady rate in the long run. Despite challenges in the healthcare sector, Humana's profitability metrics are better than its peers, and the company has a history of impressive dividend growth.

Humana: This Year's Drop Might Have Created A Buying Opportunity

Humana (HUM) concluded the recent trading session at $347.19, signifying a -0.28% move from its prior day's close.

Humana (HUM) Stock Slides as Market Rises: Facts to Know Before You Trade

Investors looking for stocks in the Medical - HMOs sector might want to consider either Cigna (CI) or Humana (HUM). But which of these two stocks offers value investors a better bang for their buck right now?

CI or HUM: Which Is the Better Value Stock Right Now?

Despite the market being near all-time highs, there are plenty of stocks that are in the red for the year. Many familiar names are not shared at the current rally, and they have seen their share price slump in recent months while the rest of the market ascends to new heights.

The 3 Most Undervalued S&P 500 Stocks to Buy in March 2024

Boeing

The market has enjoyed a fantastic run in 2024, building nicely on last year's gains. Up 8% YTD, the S&P 500's strong performance has been aided significantly by large-cap technology, with others also joining the party.

News for Humana Stock (HUM)